



AHCL/ SE/23/2026-27

August 11, 2026

The National Stock Exchange of India Limited "Exchange Plaza", C-1, Block G Bandra-Kurla Complex, Bandra (E) Mumbai 400 051 ISIN: INE098F01031	BSE Limited Department of Corporate Services 1 st Floor, P.J. Towers, Dalal Street, Mumbai 400 001 ISIN: INE098F01031
Symbol: AMRUTANJAN	Scrip Code: 590006

Dear Sir / Madam,

Sub: Outcome of the Board Meeting

In terms of Regulation 30 and 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (SEBI LODR), we wish to inform that the Board of Directors of the Company at its meeting held today **August 11, 2026** had inter-alia:

- (i) Approved the Unaudited Financial Results for the quarter ended June 30, 2026, as recommended by the Audit Committee at its meeting held today 11th August 2026 the same along with the Limited Review Report issued by M/s. B S R & Co. LLP, Statutory Auditors of the Company is enclosed.
- (ii) Holding the Eighty Ninth (89th) Annual General Meeting (AGM) of the Company on September 23, 2026 (Wednesday) through Video Conference ("VC")/ Other Audio Visual Means ("OAVM").
- (iii) The record date for determining the eligibility of shareholders to vote on the resolutions proposed at the 89th AGM of the Company and for the payment of the Final Dividend has been fixed as Friday, September 11, 2026.
- (iv) The Share transfer register shall be closed from Saturday, September 12, 2026 to Wednesday, September 23, 2026 (both days inclusive).

The Board Meeting commenced at 12:00 P.M and concluded at 6.10 P.M. Request you to kindly take the same on record.

Thanking you,

Yours faithfully,

For **Amrutanjan Health Care Limited**

Gagan Preet Singh
General Manager - Legal
Company Secretary and Compliance Officer

Encl:

- 1. Un-audited Standalone Financials Results for the quarter ended June 30, 2026
- 2. Limited Review Report

AMRUTANJAN HEALTH CARE LIMITED
CIN No : L24231TN1936PLC000017
Registered Office: No. 103 (Old No. 42-45), Luz Church Road
Mylapore, Chennai - 600 004

Statement of Unaudited Financial Results for the quarter ended 30 June 2026

	Particulars	(Amount in INR in Lakhs)			
		30 June 2026 (Unaudited)	Quarter ended 31 March 2026 (Audited refer note - 5)	30 June 2025 (Unaudited)	Year ended 31 March 2026 (Audited)
I	Revenue from operations	10,296.88	14,976.81	9,404.57	50,255.27
II	Other income	381.48	473.06	442.74	1,757.39
III	Total income (I + II)	10,678.36	15,449.87	9,847.31	52,012.66
IV	Expenses				
	(a) Cost of materials consumed				
	(b) Purchase of stock-in-trade	2,575.86	3,130.01	2,123.63	10,642.70
	(c) Changes in inventories of finished goods, work-in-progress and stock-in-trade	3,608.00	4,098.44	3,116.27	14,063.09
	(d) Employee benefits expense	(755.96)	123.83	(300.88)	(269.64)
	(e) Finance cost	1,762.42	1,564.93	1,601.31	6,376.25
	(f) Depreciation and amortisation expense	4.39	4.59	5.15	19.50
	(g) Other expenses	191.52	160.62	153.07	631.90
	- Advertisement and selling expenditure	781.39	1,757.98	736.94	6,003.83
	- Others	1,701.05	1,747.35	1,282.55	5,870.58
	Total expenses (IV)	9,868.67	12,587.75	8,718.04	43,338.21
V	Profit before exceptional item & tax (III - IV)	809.69	2,862.12	1,129.27	8,674.45
VI	Exceptional Item				
	Lease rent (refer Note 6)	202.75	760.50	-	760.50
	Impact of New labour codes (refer Note 7)	-	-	-	125.17
VII	Profit before tax (V - VI)	606.94	2,101.62	1,129.27	7,788.78
VIII	Tax expenses	170.37	482.34	298.15	1,997.00
IX	Profit after tax (V - VI)	436.57	1,619.28	831.12	5,791.78
X	Other comprehensive income / (loss)				
	Items that will not be reclassified subsequently to profit or loss				
	Re-measurement gain/(loss) on defined benefit plans	(46.49)	14.95	(7.52)	(18.50)
	Income tax relating to items that will not be reclassified to profit or loss	11.70	(3.76)	1.89	4.66
	Other comprehensive income/ (loss), net of taxes	(34.79)	11.19	(5.63)	(13.84)
		401.78	1,630.47	825.49	5,777.94
XI	Total comprehensive income for the period / year (VII + VIII)	289.11	289.11	289.11	289.11
	Equity share capital (Face value INR 1/- each, fully paid up)				36,734.15
	Other equity				
	Earnings per equity share	1.51	5.60	2.87	20.03
	Basic earnings per share (INR)	1.51	5.60	2.87	20.03
	Diluted earnings per share (INR)	(not annualised)	(not annualised)	(not annualised)	(annualised)

See accompanying notes to Unaudited financial results



AMRUTANJAN HEALTH CARE LIMITED
CIN No : L24231TN1936PLC000017
Registered Office: No. 103 (Old No. 42-45), Luz Church Road
Mylapore, Chennai - 600 004

Notes:

1. The above unaudited financial results for the quarter ended 30 June 2026 in respect of Amrutanjan Health Care Limited (the Company) have been reviewed by the Audit Committee and approved by the Board of Directors of the Company at their respective meetings held on 11 August 2026. The above unaudited financial results have been subjected to limited review by the statutory auditors of the Company. The auditors have issued an unmodified review report.
2. These unaudited financial results have been prepared in accordance with Indian Accounting Standards ('Ind AS') prescribed under Section 133 of the Companies Act, 2013 and other accounting principles generally accepted in India and in terms of Regulation 32 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.
3. The Company does not have any subsidiary/associate/joint venture company(ies) and hence there is no requirement to prepare Consolidated Financial Results.
4. During the financial year 2020-2021, Amrutanjan's Board of Directors had approved the Amrutanjan Health Care Limited Employee stock option scheme ('Scheme 2020') for the grant of stock options to the employees of the Company. The Compensation Committee administers the plan through a trust established specifically for this purpose, called Amrutanjan Health Care Limited ESOP trust ('ESOP trust'). The assets and liabilities of the trust is accounted for as assets and liabilities of the Company on the basis that the trust is exclusively set up for the purpose of administering the ESOP plan of the Company. Further, based on the recommendation of the Compensation Committee, the Board of Directors of the Company has approved further grants under the scheme mentioned above at its meeting held on 23 May 2024. The Compensation Committee has withdrawn the 'ESOP 2 Scheme' due to non-satisfaction of vesting conditions (Turnover) and unfavorable movement in the market price of the shares. In line with Ind AS 102, the impact of such cancellation amounting to INR 269.16 Lakhs is recognised in the Statement of Profit and Loss during the year ended 31 March 2026 such that the cumulative expense reflects the cost of vested options, with a corresponding adjustment to share based payment reserve. Further, based on the recommendation of the Compensation Committee, the Board of Directors of the Company has approved the further grants under the scheme mentioned above as 'Second Phase ESOP 2 Scheme', at its meeting held on 7 May 2025.
5. The figures for the quarter ended 31 March 2026 are the balancing figures between audited figures in respect of the full financial year and published unaudited year to date figures upto the end of the third quarter of the relevant financial year, which were subjected to limited review and not subjected to audit.
6. During the financial year 2005-06, the Government of Tamil Nadu retrospectively revised the lease rent for a leasehold land, effective from November 2001, by determining fair rent under Section 34A of the Tamil Nadu Hindu Religious and Charitable Endowments Act, 1959 (HR & CE Department). Pursuant to this revision, a demand notice was issued to the Company. Accordingly, the Company had filed a Writ Petition before the High Court of Judicature, Madras challenging the fair rent determination, contending that the revision was exorbitant and not legally tenable. On 25 September 2025, the High Court of Judicature, Madras dismissed the petition and upheld the rent fixed by the Fair Rent Committee constituted by the Government of Tamil Nadu. Based on the advice from the external consultant, the Company filed an appeal on 9 December 2025 before the Division Bench of the High Court of Judicature, Madras and the appeal was dismissed on 16 March 2026. Further, the Company filed a review petition against the said appeal and the same was also dismissed on 30 April 2026. Accordingly, the Company has created a provision for INR 760.50 lakhs for the year ended 31 March 2026. However, in July 2026, the Company has received a demand notice from HR & CE Department for INR 974.67 lakhs with arrears. After various representations, the management has settled the demand on 01 August 2026 and the consequential additional cost of INR 202.75 lakhs has been disclosed as 'Exceptional Item' in the quarter ended 30 June 2026.
7. Effective 21 November 2025, the Government of India has consolidated multiple existing labour legislations into a unified framework comprising four labour codes collectively referred to as the 'New Labour Codes'. Under Ind AS 19, changes to the employee benefits plans arising from legislative amendments constitute a plan amendment, requiring recognition of past service cost immediately in the Statement of Profit and Loss. The New Labour Codes has resulted in estimated one time increase in provision of employee benefits of the Company of INR 125.17 Lakhs and the same has been recognised as 'Exceptional item' during the year ended 31 March 2026. The Company continues to monitor developments on the Rules notified by the Regulatory authorities, including clarifications/ additional guidance from authorities and will continue to assess the accounting implications basis such developments/ guidance.
8. The unaudited financial results of the Company for the Quarter ended 30 June 2026 have been filed with the National Stock Exchange of India Limited (NSE) and BSE Limited (BSE) and are available in Company's website www.amrutanjan.com.



[Handwritten signature]

AMRUTANJAN HEALTH CARE LIMITED
CIN No : L24231TN1936PLC000017
Registered Office: No. 103 (Old No. 42-45), Luz Church Road
Mylapore, Chennai - 600 004

9 Segment reporting in the Unaudited financial results: Based on the 'management approach' as defined in Ind AS 108 'Operating Segments', the Chief Operating Decision Maker evaluates the Company's performance as OTC Products, Women's Hygiene, Beverages and Other segment (represents Pain Management Centre), pursuant to launch of New products Women's Hygiene is renamed as Women's Hygiene & Personal Care.

(Amount in INR in Lakhs)

	Particulars	Quarter ended			Year ended
		30 June 2026 (Unaudited)	31 March 2026 (Audited refer note - 5)	30 June 2025 (Unaudited)	31 March 2025 (Audited)
1	Segment revenue				
a	OTC Products	5,725.83	9,078.83	5,697.24	32,831.73
b	Women's Hygiene & Personal Care	3,635.77	4,183.90	2,880.75	13,990.66
c	Beverages	863.59	1,641.84	776.01	3,156.09
d	Others	71.69	72.44	70.57	276.79
	Total	10,296.88	14,976.81	9,404.57	50,255.27
2	Segment results				
a	OTC Products	987.44	2,671.64	1,079.14	8,344.36
b	Women's Hygiene & Personal Care	(287.61)	(128.90)	14.85	(272.16)
c	Beverages	(125.98)	81.88	(299.82)	(634.86)
d	Others	3.39	(3.56)	(4.51)	(27.64)
	Total	577.24	2,621.06	789.66	7,409.70
	Less: Finance cost	4.39	4.59	5.15	19.50
	Add: Interest income net of other unallocable expenditure	34.09	(514.85)	344.78	398.58
	Total profit before tax	606.94	2,101.62	1,129.27	7,788.78
3	Segment assets				
a	OTC Products	8,307.90	7,897.10	6,769.06	7,897.10
b	Women's Hygiene & Personal Care	15,007.23	13,593.47	5,707.88	13,593.47
c	Beverages	2,672.87	3,376.12	2,736.46	3,376.12
d	Others	130.72	120.38	125.54	120.38
e	Unallocated assets	24,185.26	25,902.03	26,562.01	25,902.03
	Total	50,303.98	50,889.10	41,900.95	50,889.10
4	Segment liabilities				
a	OTC Products	5,298.83	5,726.00	5,084.47	5,726.00
b	Women's Hygiene & Personal Care	4,569.89	4,739.52	1,289.62	4,739.52
c	Beverages	994.75	1,576.29	1,217.50	1,576.29
d	Others	50.51	36.90	52.18	36.90
e	Unallocated liabilities	1,941.28	1,787.13	726.28	1,787.13
	Total	12,855.26	13,865.84	8,370.05	13,865.84
	Total capital employed in the Company	37,448.72	37,023.26	33,530.90	37,023.26

For Amrutanjan Health Care Limited

Date: 11 August 2026
Place: Chennai



S Sambhu Prasad
Chairman & Managing Director
DIN: 00015729


Limited Review Report on unaudited financial results of Amrutanjan Health Care Limited for the quarter ended 30 June 2026 pursuant to Regulation 33 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended**To the Board of Directors of Amrutanjan Health Care Limited**

1. We have reviewed the accompanying Statement of unaudited financial results of **Amrutanjan Health Care Limited** (hereinafter referred to as "the Company") for the quarter ended 30 June 2026 ("the Statement") in which are included the unaudited financial results of Amrutanjan Health Care Limited ESOP Trust ("ESOP trust").
2. This Statement, which is the responsibility of the Company's management and approved by its Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013, and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ("Listing Regulations"). Our responsibility is to issue a report on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.
4. Attention is drawn to the fact that the figures for the three months ended 31 March 2026 as reported in the Statement are the balancing figures between audited figures in respect of the full previous financial year and the published year to date figures up to the third quarter of the previous financial year. The figures up to the end of the third quarter of previous financial year had only been reviewed and not subjected to audit.
5. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the Listing Regulations, including the manner in which it is to be disclosed, or that it contains any material misstatement.

For BSR & Co. LLP

Chartered Accountants

Firm's Registration No.: 101248WW-100022

**R Kalyana Sundara Rajan**

Partner

Chennai

11 August 2026

Membership No.: 221822

UDIN: 26221822LVGJCW9666

Registered Office

BSR & Co. (a partnership firm with Registration No. 3461223) converted into BSR & Co. LLP (a Limited Liability Partnership with LLP Registration No. AAB-8161) with effect from October 14, 2013

14th Floor, Central B Wing and North C Wing, Neeson IT Park 4, Neeson Center, Western Express Highway, Goregaon (East), Mumbai - 400063

Page 1 of 1